emeryville
(11)
Dynavax Technologies
Dynavax Technologies is an Emeryville, California biopharmaceutical company built around CpG 1018, a proprietary vaccine adjuvant that sharpens the immune system's response. Its flagship product, HEPLISAV-B, is the first and only two-dose adult hepatitis B vaccine approved in the U.S. and Europe, and had grown to roughly 44% U.S. market share by the end of 2024. Beyond hepatitis B, Dynavax licenses CpG 1018 to other vaccine developers - most visibly as an ingredient in several COVID-19 vaccines - and has advanced its own pipeline in shingles, plague, pandemic influenza, and Lyme disease. In December 2025 Sanofi agreed to acquire Dynavax for about $2.2 billion; the deal closed in February 2026.
Eureka Therapeutics, Inc.
Eureka Therapeutics is a clinical-stage biopharmaceutical company in Emeryville, California, developing next-generation T-cell therapies for cancer, with a focus on hard-to-treat solid tumors. Founded in 2006 by Dr. Cheng Liu, the company pairs its E-ALPHA phage-display antibody engine with its ARTEMIS T-cell receptor platform - an alternative to conventional CAR-T designed to keep engineered T cells potent inside immunosuppressive tumors while sharply reducing the inflammatory cytokine release linked to CAR-T toxicity. Its lead program, ECT204, targets GPC3-positive advanced liver cancer and has received FDA RMAT designation.
Brillouin Energy
Brillouin Energy is an Emeryville, California clean-technology company developing thermal energy systems based on Low Energy Nuclear Reactions (LENR). Its patented Controlled Electron Capture Reaction (CECR) process uses small amounts of hydrogen, nickel and electricity to generate heat via its Hydrogen Hot Tube (HHT) reactor and proprietary Q-Pulse control system, with helium as a negligible byproduct and no carbon emissions or radioactive waste. Founded in 2009 by Robert Godes, the company aims to commercialize licensable, ultra-clean heat for industrial process, district energy and distributed power applications.
Aepnus Technology
Aepnus Technology is an Emeryville, California cleantech startup that builds ultra-efficient, catalyst-free electrolyzers to turn sodium sulfate - a low-value waste salt produced in enormous volumes by battery-material and critical-mineral plants - back into two industrial staples: caustic soda (sodium hydroxide) and sulfuric acid. By splitting waste salt on-site with renewable electricity, Aepnus lets manufacturers cut disposal costs, reduce emissions, and shorten fragile chemical supply chains, converting a roughly $350-per-tonne waste-handling problem into about $700 of usable reagents per tonne.
Abalone Bio
Abalone Bio is an Emeryville-based preclinical biotech building target-activating antibodies for diseases other drugs can't reach. Its FAST platform pairs engineered yeast cells with AI/ML to screen ~100 million antibodies per experiment for functional activity, not just binding, with an initial focus on G-protein coupled receptors (GPCRs) and metabolic disease.
Max Cao
Max Cao is the co-founder and CEO of Jacobi Robotics, an Emeryville, California startup building AI-first software that programs industrial robot arms up to 20x faster. A mechanical engineer trained at Imperial College London and UC Berkeley's BAIR Lab under Ken Goldberg, and a former McKinsey consultant, Cao left academia to attack a problem most people never see: the way robots are programmed has barely changed since the 1980s. Jacobi's motion-planning technology cuts deployment from a month to under a day, claims 1000x less compute, and handles the singularities that freeze robot arms mid-task. The company launched publicly in July 2024 with a $5M seed round led by Moxxie Ventures.
Shawn Manchester
Shawn Manchester is the CEO of Triplebar, an Emeryville-and-Oakland based biotech building generative AI 'genome language models' paired with ultra-high-throughput phenotypic screening to slash the cost of biologic therapeutics and food proteins. A chemical engineer by training (BS Brown, PhD MIT), he was the lead scientist in the first AI-versus-human strain engineering contest at Zymergen before joining Triplebar in 2021, where he rose from VP of Product to COO to CEO in March 2025.
Michael Harrington
Michael Harrington is the Chief Executive Officer, Practice Management at Vituity, the physician-owned, multispecialty partnership headquartered in Emeryville, California. An accountant by training, he has spent more than three decades inside healthcare operations and stepped into the CEO role in 2002 after years as Vituity's CFO.
Babylist
Babylist is the operating system for new parenthood — a universal baby registry that grew into an ecommerce destination, a content engine, a healthcare brand, and now a chain of experiential showrooms. Founded in 2011 by ex-Amazon engineer Natalie Gordon, the company hit $750M in 2025 revenue while staying founder-led, profitable, and unapologetically focused on the parent.
Cheng Liu
Cheng Liu is the founder, President, and CEO of Eureka Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Emeryville, California. A molecular cell biologist trained at UC Berkeley and Peking University, Liu invented a novel class of TCR mimic antibodies that allow engineered T cells to recognize intracellular tumor antigens - a major challenge in treating solid tumors. Since founding Eureka in 2006 after a decade at Chiron/Novartis, he has built a pipeline of ARTEMIS T-cell therapies targeting liver cancer, multiple myeloma, and neuroblastoma, with the company's ECT204 program earning FDA RMAT Designation in January 2026 - one of the highest-priority designations the FDA gives to regenerative medicine therapies. Eureka has raised over $168 million in total funding and holds more than 500 patents worldwide.
Ryan Spencer
Ryan Spencer is the CEO of Dynavax Technologies, the Emeryville biotech behind HEPLISAV-B and the CpG 1018 adjuvant. He joined as an interim controller in 2005, climbed for fourteen years through finance, IR, and commercial roles, and took the top job in December 2019. Under him, Dynavax supplied adjuvant for nearly a billion COVID-19 vaccine doses and, in December 2025, agreed to be acquired by Sanofi for roughly $2.2 billion.